News

Eli Lilly: I've Learned Not To Fight Against The Market (Downgrade)
Eli Lilly faces market headwinds, slowing growth, and rising competition. Discover why now might be the time for LLY ...
Healthy Returns: New weight loss drug data show Eli Lilly is gaining ground
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...
3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow
Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...
Buy Eli Lilly While The Market Hesitates And Let Time Make You Dominate
Eli Lilly poised for 30-50% growth in 12 months with a strong value and growth nexus. Click here to read more on LLY stock.
GlobalData on MSN10h
Eli Lilly receives FDA approval for Amyvid label update
The US Food and Drug Administration (FDA) has granted approval for a label update to Eli Lilly and Company's Amyvid ...
PharmExec5h
FDA Expands Eli Lilly’s Amyvid Label to Guide Alzheimer Treatment Decisions
The label update for Amyvid adds guidance for assessing amyloid plaque levels and may help inform diagnostic and treatment ...
Eli Lilly Just Made Another Move to Dominate the Weight Loss Market: Should You Buy the Stock?
Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...
Chinese Biotech Showcases Challenger to Eli Lilly’s Obesity Drug
An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new ...
StockStory.org on MSN15h
5 Revealing Analyst Questions From Eli Lilly’s Q1 Earnings Call
Eli Lilly’s first quarter saw rapid revenue growth, but the market responded negatively due to profit shortfalls and emerging ...